Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol vs iron sucrose for pediatric iron deficiency anemia
2024-516264-28-00Phase 3Authorised
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Aug 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ferumoxytol in iron deficiency anemia (IDA) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoints: Incidence of adverse events of special interest, Incidence of serious adverse events and 5 more. Planned start Aug 2024; status: authorised.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2024-516264-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516264-28-00.